ZA200201044B - Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent. - Google Patents

Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent.

Info

Publication number
ZA200201044B
ZA200201044B ZA200201044A ZA200201044A ZA200201044B ZA 200201044 B ZA200201044 B ZA 200201044B ZA 200201044 A ZA200201044 A ZA 200201044A ZA 200201044 A ZA200201044 A ZA 200201044A ZA 200201044 B ZA200201044 B ZA 200201044B
Authority
ZA
South Africa
Prior art keywords
oxazole
promoting agent
thiazole derivatives
secretion promoting
neurotrophin production
Prior art date
Application number
ZA200201044A
Other languages
English (en)
Inventor
Yu Momose
Katsuhito Murase
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of ZA200201044B publication Critical patent/ZA200201044B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/38—One oxygen atom attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ZA200201044A 1999-08-25 2002-02-06 Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent. ZA200201044B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23891799 1999-08-25

Publications (1)

Publication Number Publication Date
ZA200201044B true ZA200201044B (en) 2003-04-30

Family

ID=17037204

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200201044A ZA200201044B (en) 1999-08-25 2002-02-06 Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent.

Country Status (29)

Country Link
US (3) US6605629B1 (xx)
EP (1) EP1206472B1 (xx)
JP (2) JP3558588B2 (xx)
KR (3) KR20020060066A (xx)
CN (1) CN1291985C (xx)
AR (1) AR035016A1 (xx)
AT (1) ATE251156T1 (xx)
AU (1) AU780307B2 (xx)
BR (1) BR0013493B1 (xx)
CA (1) CA2382355C (xx)
CZ (1) CZ303101B6 (xx)
DE (1) DE60005695T2 (xx)
DK (1) DK1206472T3 (xx)
ES (1) ES2206292T3 (xx)
HK (1) HK1044762B (xx)
HU (1) HU228507B1 (xx)
IL (2) IL148020A0 (xx)
MX (1) MXPA01013453A (xx)
MY (1) MY128113A (xx)
NO (1) NO322499B1 (xx)
PE (1) PE20010527A1 (xx)
PL (1) PL205532B1 (xx)
PT (1) PT1206472E (xx)
RU (1) RU2260003C2 (xx)
SI (1) SI1206472T1 (xx)
SK (1) SK285938B6 (xx)
TW (1) TWI268929B (xx)
WO (1) WO2001014372A2 (xx)
ZA (1) ZA200201044B (xx)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035016A1 (es) * 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
JP4590159B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法
ATE442148T1 (de) 2001-04-04 2009-09-15 Ortho Mcneil Janssen Pharm Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
CA2452114C (en) * 2001-06-26 2010-11-16 Takeda Chemical Industries, Ltd. Tgf-.beta. superfamily production/secretion promoter
WO2003057215A1 (fr) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Accelerateur de production/secretion de facteur neurotrophique
GB0203412D0 (en) * 2002-02-13 2002-04-03 Pharmagene Lab Ltd 5-HT 2B receptor antagonists
AU2003211385A1 (en) 2002-02-28 2003-09-09 Takeda Chemical Industries, Ltd. Azole compounds
ES2434493T3 (es) * 2002-03-14 2013-12-16 Takeda Pharmaceutical Company Limited Regulador del VDAC
JP4484439B2 (ja) * 2002-03-14 2010-06-16 国立大学法人東京工業大学 Ｖｄａｃ調節剤
RU2337682C2 (ru) 2002-11-01 2008-11-10 Такеда Фармасьютикал Компани Лимитед Средство для профилактики или лечения невропатии
EP2385032A1 (en) 2002-11-08 2011-11-09 Takeda Pharmaceutical Company Limited GPR40 Receptor function regulator
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US20090117181A1 (en) * 2003-06-25 2009-05-07 Tomoyuki Uehara Tablet comprising fluvastatin and carmellose calcium
ATE361294T1 (de) * 2003-08-20 2007-05-15 Lilly Co Eli Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagonartigen peptid (glp)-1-verbindung oder eines melanocortin-4- rezeptor-(mc4-)agonistschen peptids
EP1658273B1 (en) * 2003-08-20 2007-01-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
WO2005041962A1 (en) 2003-10-31 2005-05-12 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
CN1902196B (zh) * 2003-12-26 2010-12-29 协和发酵麒麟株式会社 噻唑衍生物
EP1711496A4 (en) * 2004-01-28 2009-02-11 Smithkline Beecham Corp THIAZOLE COMPOUNDS
WO2005076695A2 (en) * 2004-02-11 2005-08-25 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
WO2005095338A1 (ja) 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited アルコキシフェニルプロパン酸誘導体
WO2005097113A2 (en) * 2004-04-08 2005-10-20 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
JP5094394B2 (ja) 2005-04-20 2012-12-12 武田薬品工業株式会社 縮合複素環化合物
EP1876179B1 (en) 2005-04-28 2015-03-25 Takeda Pharmaceutical Company Limited Thienopyrimidone compounds
ES2434072T3 (es) 2005-06-09 2013-12-13 Norgine Bv Preparación sólida de 2-hexadeciloxi-6-metil-4H-3,1-benzoxacin-4-ona
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
EP1894930A4 (en) * 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd THIAZOLE DERIVATIVE
MY159522A (en) 2005-09-14 2017-01-13 Takeda Pharmaceuticals Co Administration of dipeptidyl peptidase inhibitors
JP5094416B2 (ja) 2005-12-28 2012-12-12 武田薬品工業株式会社 糖尿病治療剤
CA2648748A1 (en) 2006-04-14 2007-10-25 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
RU2444521C2 (ru) 2006-06-27 2012-03-10 Такеда Фармасьютикал Компани Лимитед Конденсированные циклические соединения
CN101096363B (zh) * 2006-06-27 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途
EP2058309A4 (en) 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
NZ576570A (en) 2006-10-19 2010-11-26 Takeda Pharmaceutical 7-sulfonylamino-2-thiazol and 2-thiadiazol -indole compounds
JP2010510962A (ja) 2006-11-24 2010-04-08 武田薬品工業株式会社 複素単環化合物およびその用途
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP2128163A1 (en) 2007-01-25 2009-12-02 Takeda Pharmaceutical Company Limited Spiro-ring compound
JPWO2008093639A1 (ja) 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
EP2123652A1 (en) 2007-02-20 2009-11-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
WO2009015917A2 (en) * 2007-05-14 2009-02-05 F. Hoffmann-La Roche Ag Dihydroquinone and dihydronaphthridine inhibitors of jnk
WO2008143262A1 (ja) 2007-05-21 2008-11-27 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
TW200914006A (en) 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
CN101754962B (zh) 2007-07-19 2013-12-25 赛马拜制药公司 作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
NZ583346A (en) 2007-07-19 2012-02-24 Takeda Pharmaceutical Solid preparation comprising alogliptin and metformin hydrochloride
WO2009038110A1 (ja) 2007-09-19 2009-03-26 Nagoya Industrial Science Research Institute 神経栄養因子様作用剤
US8586571B2 (en) 2007-10-18 2013-11-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2009057784A1 (ja) 2007-11-01 2009-05-07 Takeda Pharmaceutical Company Limited 複素環化合物
EP2229939A4 (en) 2008-01-10 2011-04-27 Takeda Pharmaceutical CAPSULE FORMULATION
EA019752B1 (ru) 2008-03-05 2014-06-30 Такеда Фармасьютикал Компани Лимитед Гетероциклическое амидное соединение и его применение для лечения/профилактики диабета
WO2009123194A1 (ja) 2008-04-01 2009-10-08 武田薬品工業株式会社 複素環化合物
EP2264017A4 (en) 2008-04-04 2011-07-27 Takeda Pharmaceutical Heterocyclic derivative and its use
EP2266983B1 (en) 2008-04-16 2013-06-05 Takeda Pharmaceutical Company Limited Nitrogenated 5-membered heterocyclic compound
CN102112440A (zh) 2008-05-30 2011-06-29 武田药品工业株式会社 杂环化合物
US20110136788A1 (en) 2008-08-07 2011-06-09 Minoru Maruyama Therapeutic agent for irritable bowel syndrome
UY32126A (es) 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
EP2351743A4 (en) 2008-10-27 2012-05-09 Takeda Pharmaceutical BICYCLIC CONNECTION
EP2371826A4 (en) 2008-12-29 2012-06-27 Takeda Pharmaceutical NEW CONNECTION WITH CONDENSED RINGS AND ITS USE
US20100190747A1 (en) 2009-01-27 2010-07-29 Hideo Suzuki Fused ring compound and use thereof
KR20120006545A (ko) 2009-04-16 2012-01-18 다케다 야쿠힌 고교 가부시키가이샤 당뇨병의 예방 또는 치료에 특히 유용한 ｎ―아실―ｎ’―페닐피페라진의 유도체
JP2010254623A (ja) 2009-04-24 2010-11-11 Takeda Chem Ind Ltd ベンゾオキサジノン化合物の結晶
US20100307042A1 (en) 2009-06-05 2010-12-09 Michael Brent Jarboe Modular firearm stock system
JP5657578B2 (ja) 2009-06-09 2015-01-21 武田薬品工業株式会社 新規な縮合環化合物およびその用途
US20120129878A1 (en) 2009-07-28 2012-05-24 Takeda Pharmaceutical Company Limited Tablet
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
CA2775840C (en) 2009-10-01 2018-02-06 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US8802695B2 (en) 2010-02-03 2014-08-12 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
NZ603777A (en) 2010-04-27 2013-08-30 Takeda Pharmaceutical Bicyclic compound derivatives and their use as acc inhibitors.
EA022094B1 (ru) 2010-06-16 2015-10-30 Такеда Фармасьютикал Компани Лимитед Кристаллическая форма амидного соединения
WO2012011591A1 (ja) 2010-07-23 2012-01-26 武田薬品工業株式会社 縮合複素環化合物およびその用途
JP2012050904A (ja) * 2010-08-31 2012-03-15 Panasonic Electric Works Co Ltd 浄水カートリッジ、当該浄水カートリッジを備えた浄水装置および当該浄水装置を備えた流し台
JP5816626B2 (ja) 2010-09-17 2015-11-18 武田薬品工業株式会社 糖尿病治療剤
JP2013209295A (ja) 2010-10-13 2013-10-10 Takeda Chem Ind Ltd ペプチド誘導体
US8987486B2 (en) 2010-11-02 2015-03-24 Nagoya Industrial Science Research Institute Trans-2-decenoic acid derivative and pharmaceutical agent containing the same
AR084032A1 (es) 2010-11-30 2013-04-17 Takeda Pharmaceutical Compuesto biciclico
JP2012158527A (ja) * 2011-01-31 2012-08-23 Mitsubishi Gas Chemical Co Inc うつ予防
EP2675774A1 (en) 2011-02-17 2013-12-25 Takeda Pharmaceutical Company Limited Production method of optically active dihydrobenzofuran derivative
TW201311679A (zh) 2011-08-04 2013-03-16 Takeda Pharmaceutical 含氮雜環化合物
SG2014010417A (en) 2011-10-07 2014-06-27 Takeda Pharmaceutical 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
EP2772485A4 (en) 2011-10-24 2015-06-10 Takeda Pharmaceutical BICYCLIC CONNECTION
US9365540B2 (en) 2012-01-12 2016-06-14 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as MCH receptor antagonists
US9181186B2 (en) 2012-02-13 2015-11-10 Takeda Pharmaceutical Company Limited Aromatic ring compound
JP6095580B2 (ja) 2012-02-13 2017-03-15 武田薬品工業株式会社 芳香環化合物
JP6077555B2 (ja) 2012-02-15 2017-02-08 武田薬品工業株式会社 錠剤
EP2838891B1 (en) 2012-02-24 2017-08-02 Takeda Pharmaceutical Company Limited Aromatic ring compound as ghrelin o-acyltransferase inhibitor
JPWO2013147026A1 (ja) 2012-03-29 2015-12-14 武田薬品工業株式会社 芳香環化合物
WO2013168760A1 (ja) 2012-05-10 2013-11-14 武田薬品工業株式会社 芳香環化合物
EP2848621A4 (en) 2012-05-10 2016-06-01 Takeda Pharmaceutical AROMATIC CYCLIC COMPOUND
KR102145641B1 (ko) 2012-06-05 2020-08-18 다케다 야쿠힌 고교 가부시키가이샤 고형 제제
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EP2871179A4 (en) 2012-07-03 2016-03-16 Ono Pharmaceutical Co CONNECTION WITH AGONISTIC EFFECT ON THE SOMATOSTATIN RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
JP2015127299A (ja) 2012-07-19 2015-07-09 武田薬品工業株式会社 固形製剤
EP2889291A4 (en) 2012-08-24 2015-10-14 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
US8844185B2 (en) 2012-08-27 2014-09-30 Ra Brands, L.L.C. Buttstock assembly
USD704294S1 (en) 2012-09-19 2014-05-06 Ra Brands, L.L.C. Buttstock
JP6249952B2 (ja) 2012-10-16 2017-12-20 武田薬品工業株式会社 複素環化合物
WO2014142363A1 (en) 2013-03-14 2014-09-18 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists
WO2014163161A1 (ja) 2013-04-04 2014-10-09 武田薬品工業株式会社 複素環化合物
EP2982670B1 (en) 2013-04-04 2018-11-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
TW201536767A (zh) 2013-07-09 2015-10-01 Takeda Pharmaceutical 雜環化合物
ES2672992T3 (es) 2013-08-09 2018-06-19 Takeda Pharmaceutical Company Limited Compuesto aromático
WO2015046482A1 (ja) 2013-09-30 2015-04-02 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
EP3152198B1 (en) 2014-06-09 2019-02-27 Takeda Pharmaceutical Company Limited Radiolabeled compounds
SI3210973T1 (sl) 2014-10-24 2021-04-30 Takeda Pharmaceutical Company Limited Heteroarilne spojine za zdravljenje oftalmičnih bolezni
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
RU2019124888A (ru) 2017-02-08 2021-03-10 Оно Фармасьютикал Ко., Лтд. Соединение, имеющее агонистическую активность в отношении рецептора соматостатина, и его фармацевтическое применение
JOP20180029A1 (ar) 2017-03-30 2019-01-30 Takeda Pharmaceuticals Co مركب حلقي غير متجانس
AR111199A1 (es) 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
CA3058578A1 (en) 2017-03-31 2018-10-04 Takeda Pharmaceutical Company Limited Aromatic compound
CN109020808B (zh) * 2017-06-12 2021-07-06 浙江九洲药业股份有限公司 一种取代苯乙酸衍生物的制备方法
CA3089566A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of gastrointestinal stromal tumors
JP6773938B2 (ja) 2018-08-27 2020-10-21 株式会社スコヒアファーマ 安息香酸エステル化合物
US20220016215A1 (en) 2018-09-24 2022-01-20 Takeda Phaarmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
JP2022503793A (ja) 2018-09-24 2022-01-12 武田薬品工業株式会社 Ｇｉｐ受容体アゴニストペプチド化合物及びその使用
TW202110824A (zh) 2019-05-24 2021-03-16 美商賽吉醫療公司 化合物、組合物及使用方法
CN114615982A (zh) 2019-08-12 2022-06-10 德西费拉制药有限责任公司 用于治疗胃肠道间质瘤的瑞普替尼
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
CN115243681A (zh) 2019-12-30 2022-10-25 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
LT4084778T (lt) 2019-12-30 2024-01-25 Deciphera Pharmaceuticals, Llc Amorfinės kinazės inhibitoriaus vaistinės formos ir jų panaudojimo būdai
IL296592A (en) 2020-03-25 2022-11-01 Takeda Pharmaceuticals Co One-day doses of gip receptor agonistic peptides and their uses
TW202313666A (zh) 2021-05-13 2023-04-01 美商卡默療法股份有限公司 G-蛋白偶聯受體之調節劑
CN114306291B (zh) * 2022-01-13 2023-06-27 云南大学 一种化合物在预防和/或治疗癌症中的用途
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3575991A (en) * 1969-03-11 1971-04-20 American Home Prod 1-(4-aryl - 5 - carboxymethyl-2-thiazolyl)-1,6-dihydro -6 - oxonicotinic acids and esters thereof
JPS5188964A (ja) * 1975-01-30 1976-08-04 Chiazorirusakusanjudotaino seizoho
GB1574583A (en) * 1978-02-09 1980-09-10 Wyeth John & Brother Ltd Process for preparing thiazoles
AU6610081A (en) 1980-01-24 1981-07-30 Senju Pharmaceutical Co., Ltd. Thiazolidine derivatives
JPH0725754B2 (ja) 1986-01-30 1995-03-22 富山化学工業株式会社 新規なチアゾール化合物またはその塩
JPS62234018A (ja) 1986-04-02 1987-10-14 Rooto Seiyaku Kk 糖尿病併発症治療剤
DE69313316T2 (de) 1992-02-07 1998-02-19 Mitsubishi Gas Chemical Co Verwendung von Oxazopyrrolochinolinen und Pyrrolochinolonchinonen zur Herstellung von Produktionsbeschleunigern von Nervenwachstumsfaktoren g
SE9302332D0 (sv) 1993-07-06 1993-07-06 Ab Astra New compounds
JP3362494B2 (ja) * 1994-03-01 2003-01-07 三菱ウェルファーマ株式会社 ベンゾオキサジン化合物
JPH08175992A (ja) * 1994-12-21 1996-07-09 Sagami Chem Res Center 神経成長因子産生促進剤および縮環型オキサゾール化合物
US6177452B1 (en) 1996-04-03 2001-01-23 Takeda Chemical Industries, Ltd. Oxazole derivatives, their production and use
JP4289688B2 (ja) * 1996-04-03 2009-07-01 武田薬品工業株式会社 オキサゾール誘導体、その製造法および剤
US5952360A (en) 1997-08-28 1999-09-14 Eli Lilly And Company Method for treating neuropathic pain
WO1999016460A2 (en) * 1997-09-30 1999-04-08 Duke University Apolipoprotein e/growth factor complexes and methods of use
IL140422A0 (en) 1998-07-01 2002-02-10 Retinoid Related Receptor Func Retinoid-related receptor function regulating agent
AR035016A1 (es) * 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CN1204128C (zh) 1999-09-16 2005-06-01 武田药品工业株式会社 制备噁唑衍生物的方法

Also Published As

Publication number Publication date
SK285938B6 (sk) 2007-11-02
AU6727600A (en) 2001-03-19
SI1206472T1 (en) 2004-02-29
CA2382355A1 (en) 2001-03-01
HU228507B1 (hu) 2013-03-28
DK1206472T3 (da) 2004-01-12
CZ303101B6 (cs) 2012-04-04
WO2001014372A3 (en) 2002-03-21
CN1372557A (zh) 2002-10-02
US20080269219A1 (en) 2008-10-30
TWI268929B (en) 2006-12-21
HUP0302046A3 (en) 2007-03-28
IL148020A (en) 2007-02-11
BR0013493A (pt) 2002-05-14
DE60005695T2 (de) 2004-08-19
CA2382355C (en) 2010-06-22
SK2472002A3 (en) 2002-07-02
NO322499B1 (no) 2006-10-16
US8067453B2 (en) 2011-11-29
KR20040101549A (ko) 2004-12-02
MY128113A (en) 2007-01-31
US7396848B1 (en) 2008-07-08
PL354333A1 (en) 2004-01-12
AU780307B2 (en) 2005-03-17
NO20020831D0 (no) 2002-02-20
JP2001131161A (ja) 2001-05-15
KR100486331B1 (ko) 2005-04-29
CN1291985C (zh) 2006-12-27
IL148020A0 (en) 2002-09-12
CZ2002446A3 (cs) 2002-06-12
HK1044762A1 (en) 2002-11-01
ATE251156T1 (de) 2003-10-15
KR20050043933A (ko) 2005-05-11
EP1206472B1 (en) 2003-10-01
US6605629B1 (en) 2003-08-12
PT1206472E (pt) 2004-06-30
RU2260003C2 (ru) 2005-09-10
BR0013493B1 (pt) 2013-10-01
HK1044762B (zh) 2004-01-21
DE60005695D1 (de) 2003-11-06
WO2001014372A2 (en) 2001-03-01
JP3558588B2 (ja) 2004-08-25
NO20020831L (no) 2002-04-24
JP2002080467A (ja) 2002-03-19
ES2206292T3 (es) 2004-05-16
PE20010527A1 (es) 2001-05-18
PL205532B1 (pl) 2010-04-30
KR100667646B1 (ko) 2007-01-12
EP1206472A1 (en) 2002-05-22
AR035016A1 (es) 2004-04-14
HUP0302046A2 (hu) 2003-10-28
MXPA01013453A (es) 2002-11-22
KR20020060066A (ko) 2002-07-16

Similar Documents

Publication Publication Date Title
ZA200201044B (en) Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent.
HK1042897A1 (en) Thiazole and oxazole derivatives and their pharmaceutical use.
HK1047435A1 (en) Substituted oxazoles and thiazoles derivatives as hppar alpha activators.
IL147939A0 (en) Oxazole and thiazole derivatives and pharmaceutical compositions containing the same
IL143349A0 (en) Azepinoindole derivatives, the production and use thereof
HRP20010773B1 (en) Thiazolidinedione derivative and its use as antidiabetic
AU2001292285A1 (en) Thiazole or oxazole derivatives
AP2001002329A0 (en) Thiazolidinedione derivative and its use as antibiotic
AP2002002512A0 (en) Novel thiazolidinedione
HRP20010770B1 (en) Thiazolidinedione derivative and its use as antidiabetic
PL351115A1 (en) Thiazolidinedione derivative and its use as antidiabetic
HU0001397D0 (en) 3-amino-3-arylpropan-1-ol derivatives, production and use thereof
DE60032986D1 (de) Wärmeempfindliche Schablone sowie ihr Herstellungsverfahren
AU7961800A (en) Thiazolidinedione derivatives
SI1189895T1 (sl) Tiazolni in oksazolni derivati in njihova farmacevtska uporaba
SI1173434T1 (en) Thiazolidinedione derivative and its use as antidiabetic
SI1001951T1 (en) Thiazole derivatives, method for their production and use